Clinical Trial Update: LAS41005 in Hyperkeratotic Actinic Keratosis [Phase 2]

View source ↗

Summary

A Phase 2 study of LAS41005 for actinic keratosis has completed; the update does not provide efficacy results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• LAS41005

Snippet

Sponsor: Almirall, S.A. | Conditions: Actinic Keratosis | Phase 2 | Status: COMPLETED